Kite Pharma, Inc. Insider Trading for March 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for March 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 10,000 | 13,500 | 145,394 | |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 78.75 | 400 | 31,500 | 117,795 | 118.2 K to 117.8 K (-0.34 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 78.10 | 4,925 | 384,643 | 118,195 | 123.1 K to 118.2 K (-4.00 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 77.23 | 4,375 | 337,881 | 123,120 | 127.5 K to 123.1 K (-3.43 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 75.74 | 300 | 22,722 | 127,495 | 127.8 K to 127.5 K (-0.23 %) |
| Mar 28 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 10,000 | 13,500 | 127,795 | 117.8 K to 127.8 K (+8.49 %) |
| Mar 16 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | A | 83.89 | 17,130 | 1,437,036 | 17,130 | |
| Mar 16 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Grant | A | 0.00 | 4,690 | 0 | 86,340 | 81.7 K to 86.3 K (+5.74 %) |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 21,118 | 28,509 | 155,394 | |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 81.20 | 8,991 | 730,069 | 117,795 | 126.8 K to 117.8 K (-7.09 %) |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 80.47 | 12,127 | 975,860 | 126,786 | 138.9 K to 126.8 K (-8.73 %) |
| Mar 10 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 21,118 | 28,509 | 138,913 | 117.8 K to 138.9 K (+17.93 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | M | 6.89 | 18,000 | 124,020 | 68,000 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 79.83 | 160 | 12,773 | 21,071 | 21.2 K to 21.1 K (-0.75 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 78.97 | 311 | 24,560 | 21,231 | 21.5 K to 21.2 K (-1.44 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 76.98 | 150 | 11,547 | 21,542 | 21.7 K to 21.5 K (-0.69 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 75.82 | 157 | 11,904 | 21,692 | 21.8 K to 21.7 K (-0.72 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 75.00 | 16,561 | 1,242,075 | 21,849 | 38.4 K to 21.8 K (-43.12 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 72.36 | 328 | 23,734 | 38,410 | 38.7 K to 38.4 K (-0.85 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 71.24 | 259 | 18,451 | 38,738 | 39 K to 38.7 K (-0.66 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 68.92 | 74 | 5,100 | 38,997 | 39.1 K to 39 K (-0.19 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Buy | M | 6.89 | 18,000 | 124,020 | 39,071 | 21.1 K to 39.1 K (+85.43 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 60,000 | 413,400 | 163,000 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.71 | 4,735 | 377,427 | 50,165 | 54.9 K to 50.2 K (-8.62 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.11 | 55,265 | 4,372,014 | 54,900 | 110.2 K to 54.9 K (-50.17 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 60,000 | 413,400 | 110,165 | 50.2 K to 110.2 K (+119.61 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | M | 1.35 | 50,000 | 67,500 | 75,065 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Buy | M | 1.35 | 50,000 | 67,500 | 75,065 | 25.1 K to 75.1 K (+199.48 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 76.77 | 2,800 | 214,942 | 25,065 | 27.9 K to 25.1 K (-10.05 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 77.03 | 6,000 | 462,200 | 115,017 | 121 K to 115 K (-4.96 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | S | 72.27 | 10,000 | 722,673 | 121,017 | 131 K to 121 K (-7.63 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 2,400 | 129,360 | 161,301 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 53.90 | 16,299 | 878,516 | 163,701 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | M | 51.43 | 31,601 | 1,625,239 | 52,499 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 79.92 | 400 | 31,968 | 18,664 | 19.1 K to 18.7 K (-2.10 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 79.26 | 600 | 47,556 | 19,064 | 19.7 K to 19.1 K (-3.05 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 76.93 | 200 | 15,386 | 19,664 | 19.9 K to 19.7 K (-1.01 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 75.52 | 200 | 15,104 | 19,864 | 20.1 K to 19.9 K (-1.00 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 73.64 | 100 | 7,364 | 20,064 | 20.2 K to 20.1 K (-0.50 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 72.69 | 200 | 14,538 | 20,164 | 20.4 K to 20.2 K (-0.98 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 71.23 | 200 | 14,246 | 20,364 | 20.6 K to 20.4 K (-0.97 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 70.29 | 300 | 21,087 | 20,564 | 20.9 K to 20.6 K (-1.44 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 68.95 | 200 | 13,790 | 20,864 | 21.1 K to 20.9 K (-0.95 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 2,400 | 129,360 | 21,064 | 18.7 K to 21.1 K (+12.86 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 72.60 | 300 | 21,780 | 18,664 | 19 K to 18.7 K (-1.58 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 71.65 | 1,800 | 128,970 | 18,964 | 20.8 K to 19 K (-8.67 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 71.16 | 9,049 | 643,927 | 20,764 | 29.8 K to 20.8 K (-30.35 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 69.63 | 2,553 | 177,765 | 29,813 | 32.4 K to 29.8 K (-7.89 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 68.74 | 900 | 61,866 | 32,366 | 33.3 K to 32.4 K (-2.71 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 67.49 | 2,500 | 168,725 | 33,266 | 35.8 K to 33.3 K (-6.99 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 66.32 | 10,326 | 684,820 | 35,766 | 46.1 K to 35.8 K (-22.40 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 65.81 | 18,072 | 1,189,318 | 46,092 | 64.2 K to 46.1 K (-28.17 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 63.00 | 2,400 | 151,200 | 64,164 | 66.6 K to 64.2 K (-3.61 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 53.90 | 16,299 | 878,516 | 66,564 | 50.3 K to 66.6 K (+32.43 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Buy | M | 51.43 | 31,601 | 1,625,239 | 50,265 | 18.7 K to 50.3 K (+169.32 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 28,882 | 38,991 | 176,512 | |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | M | 1.35 | 10,000 | 13,500 | 205,394 | |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 80.05 | 28,882 | 2,312,004 | 117,795 | 146.7 K to 117.8 K (-19.69 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 28,882 | 38,991 | 146,677 | 117.8 K to 146.7 K (+24.52 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 56.83 | 690 | 39,213 | 117,795 | 118.5 K to 117.8 K (-0.58 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 56.29 | 1,900 | 106,951 | 118,485 | 120.4 K to 118.5 K (-1.58 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 54.91 | 1,800 | 98,838 | 120,385 | 122.2 K to 120.4 K (-1.47 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 53.98 | 1,210 | 65,316 | 122,185 | 123.4 K to 122.2 K (-0.98 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | S | 53.15 | 4,400 | 233,860 | 123,395 | 127.8 K to 123.4 K (-3.44 %) |
| Mar 01 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Buy | M | 1.35 | 10,000 | 13,500 | 127,795 | 117.8 K to 127.8 K (+8.49 %) |